Visual function linked to preBCVA in AMD cataract patients

Article

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Related: Radiotherapy system receives CE mark extension

The US investigators studied 4,924 cataract surgeries on eyes with AMD for which preoperative and postoperative NEI-VFQ-25 questionnaires had been submitted. All were from the VA Ophthalmic Surgical Outcomes Data Project. The researchers compared outcomes in these eyes with outcomes in control eyes that did not have retinal pathology, looking at changes in visual acuity and improvement in overall visual function and its subscales.

Analysing overall scores, the investigators found that, for eyes with a preBCVA of ≥20/40, the improvement in visual function was similar to that seen in patients without retinal pathology. If the eye’s preBCVA was <20/40, however, then there was a lesser degree of improvement; the amount of improvement decreased with decreasing preBCVA. 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.